In summary, ABBV-399 (telisotuzumab vedotin, Teliso-V) represents a promising advancement in targeting c-MET-overexpressing tumor cells, demonstrating significant antitumor activity across various preclinical models, including those resistant to other c-MET inhibitors. The gene discussed is MET; the disease is neoplasm.